Table 2 Selected drug repositioning candidates
From: Drug repositioning for enzyme modulator based on human metabolite-likeness
Target Enzyme (Disease)a | Substrate | Candidate drug (Indicated Disease) | Similarity | Reference |
|---|---|---|---|---|
TYMS (Cancer) | 5,10-Methylene- tetrahydrofolate | (Levo)leucovorin (Osteosarcoma) | 0.889 | [44] |
POLA1,POLB (Leukemia) | dCTP | Decitabine (Myelodysplastic Syndromes) | 0.806 | |
DHFR (Cancer) | (6S)-5,6,7,8-tetra- hydrofolate(2-) | (Levo)leucovorin (Osteosarcoma) | 0.923 | [44] |
RRM1 (Leukemia) | CDP | Cytarabine (Leukemia) | 0.841 | [48] |
DNMT1 (Leukemia) | Cytidine | Gemcitabine (Cancer) | 0.875 | [49] |
IMPDH1/2 (Chronic Hepatitis C) | IMP | Nelarabine (Leukemia) | 0.770 | [50] |
ENPP1 (Chronic Hepatitis C) | Deamino-NAD+ | Vidarabine (Herpes virus infection) | 0.781 | [51] |
ATIC (Mesothlioma) | 10-Formyl- tetrahydrofolate | (Levo)leucovorin (Osteosarcoma) | 0.969 | [44] |
GART (Mesothlioma) | 10-Formyl- tetrahydrofolate | (Levo)leucovorin (Osteosarcoma) | 0.969 | [44] |
NME1/2 (Cancer) | dCDP | Decitabine (Myelodysplastic Syndromes) | 0.806 | [47] |
XDH (Hyperuricemia) | - | - | - | - |